Development of therapeutic cancer vaccines using nanomicellar preparations

Abstract

Abstract Cancer treatment is a multifaceted challenge, and therapeutic vaccines have emerged as a promising approach. The micellar preparation efficiently encapsulates antigen polypeptides and enhances antigen presentation through the major histocompatibility class I pathway, promoting cytotoxic T lymphocyte immune responses. Moreover, it enables codelivery of both antigen and adjuvant to the same target antigen-presenting cells. Combining the micellar vaccine with traditional cancer treatments (such as chemotherapy, radiotherapy, and surgery) has demonstrated improved efficacy in murine tumor models. Overall, the polyethylene glycol–phosphatidylethanolamine micelle-based vaccine presents a promising platform for cancer therapeutic vaccines. By leveraging the strengths of various treatment modalities, this innovative vaccine approach holds the potential to revolutionize cancer therapy and bring new possibilities for cancer patients.